NEW YORK, May 15 – Beyond Genomics said Tuesday it has entered its first corporate partnership, penning a deal with Elan Pharmaceuticalsto apply its systems biology techniques for Alzheimer's research.
In exchange for Beyond Genomics’ two-year commitment to the program, during which the companies will seek to find biomarkers and drug targets for Alzheimer's disease, Elan made a $5 million equity investment in the company.
Beyond Genomics did not disclose any more financial details.
"In addition to providing clinical expertise and support for the program, Elan will grant the joint venture a non-exclusive license to an important animal model, a mouse strain which develops many of the features of the human disease," Stephen Ober, president of Beyond Genomics, said in a statement.
Elan Pharmaceuticals said they believed Beyond Genomics’ approach to systems biology could potentially help to uncover new proteins at play in Alzherimer’s.
Beyond Genomics, a startup based in Cambridge, Mass., aims to increase the current level of throughput achieved by existing technologies and combine this capability with the ability to generate genomics, proteomics, and metabolite data.
The Company was co-founded by NewcoGen and has received $5.5 million of Series A funding from NewcoFunds and OneLiberty Ventures.